[Edaily Reporter Kim Hyung-il ] Genolution ( GENOLUTION INC.(225220)), a company specializing in green biotechnology, announced on the 12th that Co-CEO Kim Ki-ok purchased an additional 36,938 shares of the company’s stock on the open market between August 5 and 10.

CEO Kim Ki-ok’s recent on-market purchase was made with the aim of enhancing shareholder value, based on the assessment that the company’s current stock price is significantly undervalued relative to its intrinsic value.

Last July, CEO Kim Ki-ok purchased all 1,112,740 shares of GENOLUTION INC. held by Hoyl Biomed, thereby establishing firm ownership and simplifying the corporate governance structure. Immediately after resolving uncertainties in corporate governance through this change in the largest shareholder, he followed up with this on-market purchase, once again clearly demonstrating his strong commitment to responsible management.

In addition, Co-CEO Kim Min-i has consistently purchased 146,714 shares of the company’s stock on the open market in five separate transactions this year. The senior management’s continuous share buybacks, which have been ongoing since the beginning of the year, are proactive measures intended to share the company’s unwavering confidence in its future vision with shareholders and to enhance shareholder value.

In fact, GENOLUTION INC. has achieved tangible improvements in its fundamentals since the launch of the co-CEO system. Thanks to efficient decision-making leveraging the expertise of both CEOs, the company achieved a net income of 440 million won in the first quarter of this year, successfully turning a profit compared to the same period last year. In addition, regarding its core competitive strength—research and development (R&D)—the company is accelerating efforts to secure future growth engines by completing the filing of multiple patents for RNA interference (RNAi)-based crop protection agents and registering a patent for honeybee larvae rearing this year.

GENOLUTION INC. official stated, “The co-CEOs’ successive purchases of company stock stem from the top management’s shared view that the current stock price is excessively undervalued despite the company’s substantial business growth,” adding, “Building on the improved first-quarter results and patent achievements this year, we will continue to maximize the synergies of the co-CEO system to generate results from our core pipeline and enhance shareholder value.”